EGFR and neoplasm: Whereas, the ATLANTIC study [10] found that duvalumab was moderately effective in EGFR-mutated NSCLC patients who had received at least two kinds of systemic therapies including EGFR-TKI, especially in patients with PD-L1 tumor cell score (TC) ≥ 25% (TC ≥ 25% vs. TC < 25%, median OS: 13.3 vs. 9.9 months), suggesting that pre-treatment of other therapies may have impact on the efficacy of immunotherapy.